TSHA
Taysha Gene Therapies, Inc.
+0.08 (+1.68%)5.16USD1.4M成交股數1.7B市值–本益比(近四季)306.2股價營收比-100.0%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 0.00-100% | 0.00-100% | 5.5M+207% | 0.00-100% | 2.0M-42% | 2.3M-36% | 1.8M-62% | 1.1M-54% | 3.4M | 3.6M | 4.7M | 2.4M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 38.6M | 33.8M | 25.0M | 25.7M | 20.1M | 15.6M | 14.9M | 15.1M | 20.7M | 12.7M | 11.8M | 19.8M |
| 銷售管理費用 | 12.1M | 9.7M | 8.8M | 8.3M | 8.6M | 8.2M | 7.9M | 7.3M | 7.1M | 6.7M | 8.6M | 6.0M |
| 營業利益 | −47.3M+77% | −43.5M+103% | −28.3M+9% | −34.0M+60% | −26.8M+10% | −21.4M+32% | −25.9M+59% | −21.3M-9% | −24.3M | −16.2M | −16.3M | −23.4M |
| 營業利益率 | – | – | -516.0% | – | -1,347.1% | -930.5% | -1,448.4% | -1,915.4% | -713.3% | -450.8% | -342.4% | -976.4% |
| 稅後淨利 | −46.6M+73% | −42.4M+97% | −27.9M+9% | −32.7M+56% | −26.9M+12% | −21.5M-145% | −25.5M-78% | −20.9M-15% | −24.1M | 47.7M | −117M | −24.6M |
| 淨利率 | – | – | -507.8% | – | -1,353.6% | -935.2% | -1,427.5% | -1,882.0% | -705.4% | 1,324.7% | -2,467.1% | -1,027.1% |
| 稀釋 EPS | -0.13+44% | -0.12+50% | -0.08-20% | -0.090% | -0.09-10% | -0.08-113% | -0.10-89% | -0.09-76% | -0.10 | 0.63 | -0.93 | -0.38 |
| 稀釋股數 | 369M | 367M | 320M | 353M | 298M | 269M | 268M | 233M | 231M | 116M | 126M | 64.2M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 455M | 277M | 320M | 297M | 313M | 117M | 158M | 173M | 124M | 144M | 164M | 45.1M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 470M | 300M | 343M | 317M | 333M | 138M | 180M | 200M | 153M | 173M | 196M | 81.5M |
| 有息負債 | 49.3M | 49.0M | 50.1M | 50.9M | 41.1M | 42.5M | 43.0M | 37.8M | 40.5M | 40.5M | 38.5M | 38.4M |
| 總負債 | 83.2M | 88.4M | 96.4M | 97.6M | 84.6M | 83.3M | 91.4M | 91.5M | 99.2M | 97.8M | 245M | 119M |
| 股東權益 | 387M | 212M | 247M | 219M | 249M | 55.1M | 88.8M | 109M | 53.8M | 74.9M | −49.1M | −37.1M |
| 負債比 | 17.7% | 29.4% | 28.1% | 30.8% | 25.4% | 60.2% | 50.7% | 45.7% | 64.8% | 56.6% | 125.1% | 145.5% |
| 淨現金(現金 − 有息負債) | 406M | 228M | 270M | 246M | 272M | 74.1M | 115M | 135M | 83.5M | 103M | 126M | 6.7M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −40.9M+86% | – | – | – | −22.0M | – | – | −19.8M | – | – | – |
| 資本支出 | – | 24K | – | – | – | 378K | – | – | 140K | – | – | – |
| 自由現金流 | – | −40.9M+83% | – | – | – | −22.4M | – | – | −19.9M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | -973.0% | – | – | -584.5% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 9.8M | +17.3% | −109M | -1,115.3% | -0.34 | −93.8M |
| FY2024 | 8.3M | -46.1% | −89.3M | -1,071.6% | -0.36 | −81.6M |
| FY2023 | 15.5M | +517.5% | −112M | -722.1% | -0.96 | −76.9M |
| FY2022 | 2.5M | – | −166M | -6,635.3% | -3.78 | −109M |
| FY2021 | – | – | −175M | –% | -4.64 | −132M |
| FY2020 | – | – | −60.0M | –% | -3.40 | −30.8M |